EDISON EQUITY RESEARCH - BTG

Dow Jones

39,127.80

Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Get Started

Name	Symbol	Market	Type
BTG PLC (GM)	USOTC:BTGYY	OTCMarkets	Depository Receipt

	Price Change	% Change	Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Traded	Last Trade
	0.00	0.00%	11.65						0.00	01:00:00

EDISON EQUITY RESEARCH - BTG

28/05/2015 2:55pm

InvestorsHub NewsWire

EDISON EQUITY RESEARCH: ERYTECH PHARMA: BTG - RIGHT TIME, RIGHT PLACE

BTG's FY15 results demonstrate the strength of its strategy and growth prospects. It is becoming a leader in the growing interventional medicine (IM) market, with a portfolio spanning oncology, vascular and pulmonary products, targeting sales of >$1.25bn in 2021. The investment in the IM franchise is being supported by the strong cash flow from specialty pharmaceutical sales and licensing revenues. We have increased our valuation from $5.06bn to $5.36bn ($14.04/share).

BTG is a UK-based specialist healthcare company with a direct commercial presence with its interventional medicine portfolio and in US acute care medicine. It also received royalties from a number licensing agreements.

To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports